Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$71.4M Buy
283,892
+79,610
+39% +$17.1M 0.71% 28
2026
Q1
$44.4M Buy
204,282
+51,923
+34% +$11.5M 0.61% 29
2025
Q4
$34.8M Buy
152,359
+8,678
+6% +$1.98M 0.4% 52
2025
Q3
$33.3M Sell
143,681
-49,377
-26% -$10.1M 0.41% 52
2025
Q2
$35.8M Buy
193,058
+31,964
+20% +$5.94M 0.5% 43
2025
Q1
$33.8M Sell
161,094
-6,085
-4% -$1.18M 0.52% 40
2024
Q4
$29.7M Sell
167,179
-1,059
-0.6% -$195K 0.4% 52
2024
Q3
$33.2M Buy
168,238
+45,375
+37% +$8.47M 0.5% 44
2024
Q2
$21.1M Buy
122,863
+2,394
+2% +$397K 0.87% 22
2024
Q1
$21.9M Sell
120,469
-26,438
-18% -$4.56M 0.87% 24
2023
Q4
$22.8M Buy
146,907
+7,031
+5% +$1.03M 0.5% 51
2023
Q3
$20.8M Buy
139,876
+15,349
+12% +$2.25M 0.46% 58
2023
Q2
$16.8M Buy
124,527
+35,103
+39% +$5.15M 0.4% 75
2023
Q1
$14.3M Sell
89,424
-4,512
-5% -$690K 0.36% 75
2022
Q4
$15.2M Buy
+93,936
New +$14.4M 0.43% 62

Other funds holding ABBV

LBP AM's ABBV Position: Q2 2026 in Review

LBP AM increased its AbbVie (ABBV) stake by 39% in Q2 2026, buying an estimated $17.1M and bringing the position to 283,892 shares worth $71.4M. The position accounts for 0.71% of the portfolio, ranked #28.

LBP AM first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • LBP AM held 283,892 shares of AbbVie worth $71.4M as of Q2 2026.
  • LBP AM bought 79,610 AbbVie shares in Q2 2026, an estimated $17.1M.
  • AbbVie made up 0.71% of LBP AM's portfolio in Q2 2026, its #28 holding.
  • LBP AM first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
  • 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on LBP AM's 13F filing for Q2 2026, filed 24 Jul 2026.